Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study

Show full item record



Permalink

http://hdl.handle.net/10138/335642

Citation

Amele , S , Peters , L , Rodger , A , Lundgren , J , Rockstroh , J , Matulionyte , R , Leen , C , Jablonowska , E , Ostergaard , L , Bhagani , S , Sarcletti , M , Clarke , A , Falconer , K , Wandeler , G , Domingo , P , Maltez , F , Zaccarelli , M , Chkhartisvili , N , Szlavik , J , Stephan , C , Fonquernie , L , Aho , I , Mocroft , A & Group , ES 2021 , ' Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study ' , JAIDS , vol. 86 , no. 2 , pp. 248-257 . https://doi.org/10.1097/QAI.0000000000002541

Title: Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study
Author: Amele, S; Peters, L; Rodger, A; Lundgren, J; Rockstroh, J; Matulionyte, R; Leen, C; Jablonowska, E; Ostergaard, L; Bhagani, S; Sarcletti, M; Clarke, A; Falconer, K; Wandeler, G; Domingo, P; Maltez, F; Zaccarelli, M; Chkhartisvili, N; Szlavik, J; Stephan, C; Fonquernie, L; Aho, I; Mocroft, A; Group, ES
Other contributor: University of Helsinki, HUS Internal Medicine and Rehabilitation

Date: 2021-02
Language: eng
Number of pages: 10
Belongs to series: JAIDS
ISSN: 1525-4135
DOI: https://doi.org/10.1097/QAI.0000000000002541
URI: http://hdl.handle.net/10138/335642
Abstract: Objectives: To investigate the effectiveness, safety, and reasons for premature discontinuation of direct-acting antivirals (DAAs) in a diverse population of HIV/hepatitis C virus (HCV) coinfected individuals in Europe. Methods: All HIV/HCV coinfected individuals in the EuroSIDA study that started interferon free DAA treatment between January 6, 2014, and January 3, 2018, with >= 12 weeks of follow-up after treatment stop were included in this analysis. Sustained virological response (SVR) was defined as a negative HCV-RNA result >= 12 weeks after stopping treatment (SVR12). Logistic regression was used to explore factors associated with SVR12. Results: 1042 individuals started interferon-free DAA treatment after 1/6/2014 and were included, 862 (82.2%) had a known response to treatment, and 789 [91.5%, 95% confidence interval (CI): 89.7 to 93.4] of which achieved SVR12. There were no differences in SVR12 across regions of Europe (P = 0.84). After adjustment, the odds of achieving SVR12 was lower in individuals that received sofosbuvir/simeprevir +/- ribavirin (RBV) [adjusted odds ratio 0.21 (95% CI: 0.08 to 0.53)] or ombitasvir/paritaprevir/dasabuvir +/- RBV [adjusted odds ratio 0.46 (95% CI: 0.22 to 1.00)] compared with sofosbuvir/ledipasvir +/- RBV. Forty-three (4.6%) individuals had one or more components of their HCV regimen stopped early, most commonly because of toxicity (n = 14); of these 14, 11 were treated with ribavirin. Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15.3%) and was related to treatment with atazanavir and ribavirin. Conclusions: Our findings from real-world data on HIV/HCV coinfected individuals across Europe show DAA treatment is well tolerated and that high rates of SVR12 can be achieved in all regions of Europe.
Subject: HIV
HCV coinfection
DAA treatment
DAA safety
SVR
Europe
HUMAN-IMMUNODEFICIENCY-VIRUS
DACLATASVIR PLUS SOFOSBUVIR
HCV
EFFICACY
LEDIPASVIR
INFECTION
MORTALITY
REGIMENS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Effectiveness_a ... m_a_Pan_European_Study.pdf 1006.Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record